> KaloBios Pharmaceuticals has added $12 million to its Series D, bringing the total to $32 million. The latest funding was led by Baxter International. Report
> NovaDel Pharma announced that Zolpimist(zolpidem tartrate) 5 mg and 10 mg oral spray has been approved by the FDA for the short-term treatment of insomnia. Release
> A journal publisher says it's looking into allegations that an article on hormone replacement therapy was written under the influence of pharma. Report
> Galapagos will get $2.8 million after expanding its development contract with GlaxoSmithKline. Report
> King Pharmaceuticals has extended its $37-a-share tender offer for Alpharma to 10 a.m. EST Dec. 29. It had been slated to expire at 5 p.m. EST on Dec. 19, at which time about 92.2% of all outstanding shares of Class A common Alpharma stock had been tendered. Release
> Elan CEO Kelly Martin (photo) visited the Wall Street Journal Health Blog, looking to do some damage control after last week's series of bad news. Report
> A University of Houston biotech spinoff was sold earlier this month for $20 million. Release
> Where Roche's Tamiflu loses, GlaxoSmithKline wins. The Centers for Disease Control and Prevention says that one strain of this year's seasonal flu, the H1N1 virus, is increasingly resistant to Tamiflu, the leading anti-influenza treatment. Report
> Sangamo BioSiences is getting $3 million in a deal to license its technology to Pfizer. Report
> Novocell has forged a non-exclusive drug discovery deal giving Pfizer access to Novocell's proprietary pancreatic progenitor cells derived from human embryonic stem cells. Release
> In something of a vindication for Genentech, the company announced 36 reports of eye infections in Canadian patients using Avastin for the off-label treatment of wet age-related macular degeneration. Report
And Finally... Researchers at Harvard University say that our experience of pain depends on whether we think someone caused the pain intentionally. Release